Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 71 clinical trials
Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

cardioembolic stroke associated with AF. A common guideline-supported practice is to combine three drugs (OAC, aspirin and clopidogrel) in a triple therapy, which is associated with high annual risk (up to 25

dabigatran
fibrillation
embolism
aspirin
clopidogrel
  • 0 views
  • 12 Nov, 2021
  • 1 location
Appropriate Duration of Anti-Platelet and Thrombotic Strategy After 12 Months in Patients With Atrial Fibrillation Treated With Drug Eluting Stents

and clopidogrel combination therapy for maintenance therapy after 1 year in patients with atrial fibrillation.

warfarin
fibrillation
embolism
apixaban
antiplatelet agents
  • 0 views
  • 23 Sep, 2021
  • 1 location
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial (HOST-IDEA)

comparison between sirolimus-eluting Orsiro stent with biodegradable polymer and polymer-free stent platform with the same antiproliferative agent, Coroflex ISAR stent system. At the same time, clopidogrel

ischemia
sirolimus
angina pectoris
biodegradable polymer
cardiac death
  • 0 views
  • 26 Jan, 2022
  • 4 locations
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study (STOPDAPT-3)

The purpose of this study is to explore the benefit of the prasugrel monotherapy without aspirin as compared with the 1-month dual therapy with aspirin and prasugrel in terms of reducing bleeding events after percutaneous coroanry intervention (PCI) using cobalt-chromium everolimus-eluting stents (CoCr-EES, XienceTM) in patients with high bleeding risk …

aspirin
acute coronary syndrome
everolimus
percutaneous coronary intervention
clopidogrel
  • 0 views
  • 23 Apr, 2022
  • 1 location
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG (PACES)

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying …

dabigatran
coronary artery bypass graft
fibrillation
apixaban
clopidogrel
  • 112 views
  • 18 Oct, 2022
  • 47 locations
VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial) (VERONICA)

The objective of the study is to establish a de-scaling strategy of P2Y12 inhibitors (P2Y12 i) with a decrease in hemorrhagic events without increasing ischemic complications based on a Platelet Function Test (PFT).

antiplatelet therapy
prasugrel
acute coronary syndrome
clopidogrel
ticagrelor
  • 0 views
  • 28 Oct, 2022
  • 18 locations
Prevention of Stroke by Left Atrial Appendage Closure in Atrial Fibrillation Patients After Intracerebral Hemorrhage

Intracerebral hemorrhage (ICH) in patients with non-valvular atrial fibrillation (NVAF) poses a particular dilemma for thromboprophylaxis. Left atrial appendage occlusion (LAAO) is a non-pharmacological approach to prevent cardiac embolism in NVAF. The risk-benefit ratio of LAAO in patients with NVAF after ICH is unknown. The aim of STROKECLOSE is to …

atrial fibrillation
intracerebral hemorrhage
fibrillation
embolism
noac
  • 1 views
  • 27 Jan, 2022
  • 1 location
A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion (TEMPO-2)

This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours. Anyone diagnosed with a minor stroke faces the possibility of long-term disability and even death, regardless of treatment. Stroke symptoms such as weakness, difficulty …

deficit
computed tomography perfusion
angiography
ischemia
transient ischemic attack
  • 110 views
  • 24 May, 2022
  • 42 locations
Drug-Coated Balloon in Patients With High Bleeding Risk (DCB-HBR)

DCB-HBR trial is prospective, multi-center, open-label, randomized controlled, noninferiority trial. The aim of the study is to compare clinical outcomes of drug-coated balloon (DCB) with drug-eluting stent (DES) for treatment of de-novo coronary lesion under intravascular imaging-guided optimization in patients with high bleeding risk (HBR).

stenosis
aspirin
revascularisation
dapt
percutaneous coronary intervention
  • 0 views
  • 07 Oct, 2022
  • 1 location
Left Atrial Appendage Occlusion for AF Patients Unable to Use Oral Anticoagulation Therapy

Up to 5% of Atrial Fibrillation (AF) patients may have or develop contraindications to use oral anticoagulation (OAC). Randomized controlled trial (RCT) data suggest that Left Atrial Appendage Occlusion (LAAO) may provide a non-inferior alternative for cardioembolic stroke protection in patients tolerant to OAC. However, RCT data for LAAO is …

left atrial appendage occlusion
stroke
fibrillation
vascular disease
anticoagulation therapy
  • 0 views
  • 28 Sep, 2021
  • 14 locations